Applied Therapeutics is currently enrolling a Phase 1/2 study of AT-007 in adults (age 18 and older) with Galactosemia.
The study, called ACTION-Galactosemia, will investigate safety and pharmacokinetics (PK) of AT-007, a central nervous system (CNS) penetrant Aldose Reductase Inhibitor in healthy volunteers, and will then explore safety, PK and biomarker effects in adult subjects with Galactosemia.
If you are a patient or family member interested in receiving information about this trial, please email us at email@example.com
If you have questions about the trial and would like to speak to someone by phone, please call 212.220 9227.
To download FAQs about the trial, please click here.
To see our press release announcing start of the clinical trial, please click here.
To view our web page with more detail on Galactosemia research, please click here.